The frequency of chronic liver disease (CLD) is rising
Ageing population expanding Programs to raise awareness of liver illness in the public and private sectors.
The Chronic Liver Disease (CLD) Therapeutics Market in the Middle East and Turkey is anticipated to reach US$ 1,015 million in 2021 and grow at a CAGR of 5.8% from 2021 to 2028.
Key Companies in the Middle East And Turkey Chronic Liver Disease Therapeutics Industry:
1. Hoffmann-La Roche AG: Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar. Roche plans to purchase the TIB Molbiol Group, with a closing anticipated for the fourth quarter of 2021
2. Gilead Sciences, Inc.: Built in 1987. Headquarters located in Foster City, California. The primary focus of Gilead Sciences' product portfolio is on HIV and hepatitis B and C. Gilead Sciences creates and sells treatments to treat infectious diseases that are life-threatening. This focus has since been widened to encompass cancer, lung and cardiovascular disorders, and C Arresto Biosciences, V Therapeutics, and Myogen.
3. Intercept Pharmaceuticals, Inc.: The goal of the biotech company Intercept Pharmaceuticals Inc. is to create and market innovative therapies for the treatment of progressive non-viral liver disorders. Incorporated in 2002. Located in Morristown, New Jersey. The acquisition of Intercept's operations in Europe, Canada, and all other international markets is now complete by Advanz pharma.
4. Sanofi S.A: Created in 1994. Therapeutics created and distributed with patients' needs in mind. The business sells consumer healthcare items, vaccines for humans, animal health goods, and drugs for diabetes and cancer. Headquartered in France, Paris.
5. Abbott Laboratories: Abbott produces and sells branded generic pharmaceuticals, adult and paediatric nutritional items, diagnostic tools, and testing kits. Built in 1888. Head office in North Chicago, Illinois, USA.JETi (Sep 2021) Cephea Valve Technologies (Jan 2019), and St. Jude Medical (Apr 2016) are the most recent acquisitions.
